OC
OCUL.US Ocular Therapeutix Inc
- Market cap
- USD 1.37B
- P/E
- -
- P/B
- 3.09x
- ROE
- -79.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OCUL.US undervalued?
Graham numberThe Graham number of Ocular Therapeutix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ocular Therapeutix Inc fundamental analysis
No fundamental analysis for Ocular Therapeutix Inc yet.
Ocular Therapeutix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravi…
Full company profileOcular Therapeutix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ocular Therapeutix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.89M | 1.92M | 1.99M | 4.23M | 17.4M | 43.5M | 51.5M | 58.4M | 63.7M | 51.8M | 49.5M |
| Gross Profit | 1.44M | 1.47M | 1.53M | 1.90M | 15.3M | 39.1M | 47.0M | 53.2M | 58.1M | 45.2M | 43.1M |
| Operating Income | -43.3M | -61.9M | -59.1M | -85.8M | -62.8M | -78.0M | -78.7M | -82.4M | -172M | -270M | -364M |
| EBITDA | -42.1M | -59.9M | -56.0M | -77.7M | -146M | 2.54M | -61.9M | -66.4M | -176M | -250M | -331M |
| Net Income | -44.7M | -63.4M | -57.7M | -86.4M | -156M | -6.55M | -71.0M | -80.7M | -194M | -266M | -350M |
| EPS | -1.80 | -2.20 | -1.51 | -1.91 | -2.56 | -0.08 | -0.86 | -0.94 | -1.22 | -1.42 | -1.55 |
| Balance Sheet | |||||||||||
| Total Assets | 74.9M | 55.4M | 73.0M | 78.7M | 262M | 205M | 149M | 252M | 458M | 808M | 606M |
| Total Liabilities | 22.9M | 29.3M | 37.2M | 82.4M | 186M | 117M | 114M | 161M | 143M | 154M | 165M |
| Shareholders' Equity | 52.0M | 26.1M | 35.9M | -3.63M | 76.1M | 88.0M | 35.4M | 91.1M | 315M | 654M | 441M |
| Cash & Short-term Investments | 68.1M | 41.5M | 54.1M | 54.4M | 228M | 164M | 102M | 196M | 392M | 737M | 531M |
| Total Debt | 15.6M | 18.0M | 24.8M | 59.3M | 58.4M | 59.0M | 64.3M | 83.4M | 75.8M | 79.8M | 80.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.0M | -50.5M | -49.2M | -77.6M | -53.6M | -65.6M | -59.6M | -70.2M | -135M | -205M | -265M |
| Capital Expenditure | 1.92M | 8.25M | 1.89M | 2.24M | 841K | 1.19M | 3.72M | 6.09M | 1.29M | 12.0M | 14.7M |
| Free Cash Flow | -35.9M | -58.7M | -51.1M | -79.8M | -54.4M | -66.7M | -63.3M | -76.3M | -136M | -217M | -280M |
| Ratios | |||||||||||
| ROE | -86.0% | -242.4% | -160.8% | - | -204.5% | -7.4% | -200.8% | -88.6% | -61.4% | -40.6% | -79.3% |
| ROA | -59.7% | -114.4% | -79.0% | -109.7% | -59.4% | -3.2% | -47.6% | -32.0% | -42.3% | -32.9% | -57.7% |
| Net Profit Margin | -2,369.0% | -3,296.2% | -2,899.1% | -2,043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% | -706.0% |
| Debt to Equity | 0.30x | 0.69x | 0.69x | - | 0.77x | 0.67x | 1.82x | 0.92x | 0.24x | 0.12x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ocular Therapeutix Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 52.6M | 0.61 | - |
| 2022 | - | - | - |
| 2021 | USD 710K | 0.01 | - |
| 2020 | USD 747K | 0.01 | - |
| 2019 | USD 37.3M | 0.82 | - |
| 2018 | USD 297K | 0.01 | - |
| 2017 | USD 4.39M | 0.15 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ocular Therapeutix Inc
- Insiders 1.44%
- Institutions 97.12%
- Public & others 1.44%
- Shares outstanding 220M
- Free float 185M
Top funds holding OCUL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 9.70M | 4.41% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.66M | 3.03% | +0.39% | Sep 2026 |
| iShares Russell 2000 ETF | 5.47M | 2.49% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 2.70M | 1.23% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 2.61M | 1.19% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 2.26M | 1.03% | +0.40% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.67M | 0.76% | -0.38% | Oct 2026 |
| Invesco Pharmaceuticals ETF | 1.62M | 0.74% | +0.45% | Oct 2026 |
| LT Compound Global Equity IE F1 GBP Acc | 1.57M | 0.71% | 0.00% | Jun 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.48M | 0.67% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 1.44M | 0.66% | -19.96% | Sep 2026 |
| Fidelity Select Pharmaceuticals Port | 1.33M | 0.61% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.25M | 0.57% | +5.95% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 975K | 0.44% | +0.24% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 922K | 0.42% | -2.88% | Apr 2026 |
| Strategic Advisers Fidelity US TtlStk | 899K | 0.41% | +22.02% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 875K | 0.40% | +1.62% | Sep 2026 |
| Fidelity Extended Market Index | 861K | 0.39% | -0.45% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 806K | 0.37% | +2.88% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 804K | 0.37% | -1.78% | Sep 2026 |
Top institutions holding OCUL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 32.8M | 14.94% | +0.58% | Jun 2026 |
| Deep Track Capital, LP | 19.7M | 8.95% | 0.00% | Jun 2026 |
| BlackRock Inc | 19.4M | 8.81% | +20.11% | Jun 2026 |
| venBio Select Advisor LLC | 12.5M | 5.70% | +1.83% | Jun 2026 |
| SUMMER ROAD LLC | 12.5M | 5.67% | +2.09% | Sep 2026 |
| VR Adviser, LLC | 10.3M | 4.71% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.83M | 4.02% | +1.30% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 7.62M | 3.47% | +29.27% | Jun 2026 |
| Logos Global Management LP | 5.30M | 2.41% | +37.66% | Jun 2026 |
| State Street Corp | 5.23M | 2.38% | +11.15% | Jun 2026 |
| Geode Capital Management, LLC | 5.02M | 2.28% | +10.86% | Jun 2026 |
| Point72 Asset Management, L.P. | 3.29M | 1.50% | -40.52% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.96M | 1.35% | +6.41% | Sep 2026 |
| Deltec Asset Management LLC | 2.48M | 1.13% | +5.79% | Jun 2026 |
| Balyasny Asset Management LLC | 2.27M | 1.03% | -15.67% | Jun 2026 |
| Octagon Capital Advisors LP | 2.08M | 0.94% | -34.47% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.97M | 0.90% | +23.73% | Jun 2026 |
| Northern Trust Corp | 1.80M | 0.82% | +17.95% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.76M | 0.80% | +58.66% | Jun 2026 |
| Nuveen, LLC | 1.70M | 0.77% | +312.88% | Jun 2026 |
Ocular Therapeutix Inc company profile
- Company name
- Ocular Therapeutix Inc
- Ticker
- OCUL.US
- Exchange
- USA Stocks
- Listed since
- Jul 25, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 325
- Fiscal year end
- December
- Address
- 14 Crosby Drive, Bedford, MA, United States, 01730
- Phone
- 781 357 4000
- Website
- ocutx.com
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix Inc management
10- Dr. Pravin U. Dugel M.D.Executive Chairman, President & CEO · born 1964
- Mr. Donald Notman Jr.Chief Operating Officer (Leave of Absence)
- Mr. Steve MeyersChief Commercial Officer
- Dr. Nadia K. Waheed M.D., M.P.H.Chief Medical Officer · born 1977
- Mr. Jason RobinsCFO & Principal Accounting Officer · born 1977
- Dr. Peter K. Jarrett Ph.D.Chief Technical Officer · born 1957
- Dr. Jeffrey S. Heier M.D.Chief Scientific Officer · born 1961
- Mr. William S. Slattery Jr.Vice President of Investor Relations
- Mr. Todd D.C. Anderman J.D.Chief Legal Officer & Corporate Secretary · born 1982
- Mr. William H. Ransone IIVice President of Global Sales & Marketing